Bert Vogelstein - Nanotechnology

Author Information

Bert Vogelstein is a renowned researcher affiliated with the Ludwig Center and the Howard Hughes Medical Institute at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine. His work is primarily based in Baltimore, Maryland, where he engages in groundbreaking research, particularly in the field of cancer genetics and therapeutics.

Research Contributions

Bert Vogelstein has made significant contributions to the fields of cancer research and molecular genetics. His research encompasses a wide range of topics, including cancer immunotherapy, the development of non-invasive diagnostic assays, and the investigation of mutational signatures associated with various etiological factors in cancer. Notably, his recent work involves the development of bispecific antibodies targeting the HIV-1 reservoir, strategies to prevent hyperinflammation from respiratory infections, and the use of circulating tumor DNA for informing chemotherapy decisions in colon cancer. Vogelstein's pioneering efforts have significantly advanced our understanding of cancer biology and treatment.

Aliases

Bert Vogelstein is also known in academic circles by several variations of his name, including B Vogelstein and B. Vogelstein. These aliases are commonly used in scientific publications and citations.

Publication and Citation Metrics

Metrics	Value
Total Citation Count	364,928
h-index	269
Total Paper Count	891

Publications:

TCR-mimic bispecific antibodies to target the HIV-1 reservoir.

DOI: 10.1073/pnas.2123406119

Year: 2022

Correction to: Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology

DOI: 10.1007/s00428-022-03292-w

Year: 2022

Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection

DOI: 10.7554/eLife.61700

Year: 2021

Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer

DOI: 10.7554/eLife.61082

Year: 2021

The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19

DOI: 10.3389/fmed.2021.637647

Year: 2021

An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer Drugs

DOI: 10.1101/2021.08.06.455336

Year: 2021

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer (DYNAMIC Trial): Statistical Analysis Plan

DOI: 10.1101/2021.09.02.21262816

Year: 2021

Targeting public neoantigens for cancer immunotherapy.

DOI: 10.1038/S43018-021-00210-Y

Year: 2021

An Isogenic Cell Line Panel for Sequence-Based Screening of Targeted Anti-Cancer Drugs

DOI: 10.2139/ssrn.3936778

Year: 2021

Association of α1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark

DOI: 10.1001/jamanetworkopen.2020.37053

Year: 2021

Are There Any Risks Associated with Using Nanotechnology for Purification?

What are the Challenges in NEMS Fabrication?

What is the Tech Museum Award?

How Does Nanotechnology Improve Diagnostic Techniques?

Why are Subsidies and Grants Important in Nanotechnology?

What are the Challenges Associated with Nanotechnology in PV Cells?

What is Bayesian Optimization?

What are the Applications of Nanofibrillated Cellulose?

Why is Microscale Important in Nanotechnology?

Why is R&D so expensive in Nanotechnology?

Partnered Content Networks

Relevant Topics